BLUE-OCEAN-ROBOTICS
UVD Robots and Blue Ocean Robotics , the manufacturer of autonomous disinfecting robots equipped with UV-C light, announced today that it was selected by the European Commission directorate-Generale for Communications Networks, Content and Technology (EU Commission) to supply 200 of its autonomous disinfecting robots to European Union hospitals fighting the Coronavirus. UVD Robots’ tender ranked first in the EU Commission’s review of disinfecting robots evaluating technical excellence and maturity of technology, quality of approach in deployment, response time in technical support and maintenance, and overall value. UVD Robots are now being deployed in the first 10+ EU countries with more to follow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201207005410/en/
In a statement President of the European Commission Ursula Von Der Leyen said: “With EU funds, the European Commission is buying 200 disinfection robots, which will be delivered to hospitals across Europe to help disinfectpatient rooms. We do all we can to support hospitals and patients in these difficult times. And more will follow.”
“We are thrilled that our UVD Robots were selected by the EU Commission, which we believe to be the largest order of service robots of its kind,” said Per Juul Nielsen, CEO of UVD Robots. “We were the first robot in this category and have set the global standard for autonomous UVC disinfection. An order of this size further validates the effectiveness of UVD Robots.”
The UVD Robot disinfects against viruses and bacteria on surfaces and in the air, reducing disease transmission by killing 99.99 percent of bacteria and microorganisms within approximately 10 minutes in a patient room.
“We are helping fight the spread of Covid-19 while also strengthening prevention against Hospital Acquired Infections (HAI) overall,” said Claus Risager, CEO of Blue Ocean Robotics, UVD Robots’ parent company. “With this order, we are going even further to help protect healthcare staff, patients and relatives at hospitals at a critical moment.”
About
UVD Robots is a unique brand of one of the world's leading groups in the development of professional service robots, Blue Ocean Robotics , that also includes the brands GoBe Robots and PTR Robots . Blue Ocean Robotics is headquartered in Odense, Denmark, where it develops, produces and sells service robots.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005410/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 10:11:00 CEST | Press release
Companies aim at fuelling the local quantum ecosystem growth and promote adoption IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the c
Acuity Knowledge Partners Acquires Ascent18.9.2025 09:30:00 CEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom